oseltamivir

Oseltamivir (GS 4104) is an orally active and highly potent viral neuraminidase (NA) with antiviral activity, inhibits A/H3N2, A/H1N2, A/H1N1 and influenza B viruses, and can be used in studies of influenza and pneumonia.

Oseltamivir acid methyl ester hydrochloride is a precursor form of oseltamivir acid. Oseltamivir acid methyl ester is converted to oseltamivir acid converted by carboxylesterase 1 (CES1).

Oseltamivir phosphate (GS 4104) is the phosphate salt of oseltamivir, a synthetic derivative prodrug of ethyl ester with antiviral activity. By blocking neuraminidases on the surfaces of influenza viruses, oseltamivir interferes with host cell release of complete viral particles.

Oseltamivir acid (GS4071) is a potent influenza virus neuraminidase inhibitor and the prodrug of GS4071.

Oseltamivir carboxylate is an active metabolite of oseltamivir phosphate (Tamiflu).

Oseltamivir-d3 acid is a deuterated compound of Oseltamivir acid. Oseltamivir acid has a CAS number of 196618-13-0.

Oseltamivir acid methyl ester is a precursor form of oseltamivir acid, that converts to oseltamivir acid by carboxylesterase 1(CES1). Oseltamivir acid is the neuraminidase inhibitor and antiviral agent [1].

Oseltamivir-d3 is a deuterated compound of Oseltamivir. Oseltamivir has a CAS number of 196618-13-0. Oseltamivir (GS 4104) is an orally active and highly potent viral neuraminidase (NA) with antiviral activity, inhibits A/H3N2, A/H1N2, A/H1N1 and influenza B viruses, and can be used in studies of influenza and pneumonia.

Oseltamivir-13C-d3 Acid the 13C and deuterated compound of Oseltamivir Acid. Oseltamivir Acid has a CAS number of 187227-45-8. Oseltamivir acid (GS4071) is a potent influenza virus neuraminidase inhibitor and the prodrug of GS4071.

Oseltamivir EP Impurity C-d3 HCl is a deuterated compound of Oseltamivir EP Impurity C HCl. Oseltamivir EP Impurity C HCl has a CAS number of 1415963-60-8. Oseltamivir carboxylate is an active metabolite of oseltamivir phosphate (Tamiflu).

Oseltamivir-acetate, an impurity of Oseltamivir, is a recommended neuraminidase inhibitor for both the treatment and prophylaxis of influenza A and B[1][2].

Oseltamivir-d3 acid(3R,4S,5S) is a deuterated compound of Oseltamivir acid(3R,4S,5S).

Oseltamivirphosphate-d5 is a deuterated compound of Oseltamivirphosphate. Oseltamivirphosphate has a CAS number of 204255-11-8.

M090 is a potent inhibitor against amantadine-resistant viruses, including the 2009 H1N1 pandemic strains and oseltamivir-resistant viruses.

The binding affinities of ganoderic acid DM and ganoderic acid Z (ΔGbind, -16.83 and-10.99 kcal mol-1) are comparable to that of current commercial drug oseltamivir (-23.62 kcal mol-1);Ganoderic acid DM is a potential source of anti-influenza ingredient, with novel binding pattern and advantage over oseltamivir, it has steric hindrance on the 150 cavity of N1 protein, and exerts activities across the H274Y and N294S mutations, is the attractive candidates of novel neuraminidase (NA) inhibitors.Ganoderic acid zeta has cytotoxicity in vitro against Meth-A and LLC cell lines.

Anti-Influenza agent 5 (Compound IIB-2), a chalcone-like derivative, serves as an influenza nuclear export inhibitor. It effectively inhibits oseltamivir-resistant strains and hinders viral proliferation by obstructing the export of influenza virus nucleoprotein [1].

CAY10766 is an antiviral compound.1It inhibits entry of influenza virus-like particles pseudotyped with hemagglutinin A (HA) from H5N1 influenza A virus into A549 cells (EC50= 0.24 μM). CAY10766 (1 μM) reduces H1N1 and H5N1 influenza A viral titers in infected MDCK cells. It also exhibits synergy with oseltamivir carboxylate in MDCK cells infected with the influenza A reporter PR8-NS1-Gluc virus.

Spike Binding Peptide 1 (SBP1), representing amino acids 21-43 of angiotensin-converting enzyme 2 (ACE2), has been utilized in a novel approach involving lipid nanoparticles (LNPs) encapsulated with oseltamivir phosphate and conjugated to SBP1. This formulation aims to investigate the possibility of achieving a controlled, long-term in vivo release of oseltamivir phosphate. Furthermore, a 2% concentration of SBP1 immobilized on crosslinked networks composed of hydroxy acrylate and ethylxanthate ethyl acrylate has demonstrated enhanced in vitro efficiency in capturing the spike glycoprotein of severe acute respiratory coronavirus 2 (SARS-CoV-2), also referred to as the surface glycoprotein.

Anti-IAV Agent 1-1a is an orally administered compound effective against the Influenza A virus (IAV), demonstrating inhibitory concentration 50 (IC50) values of 0.03 μM and 0.06 μM for the H1N1 strain and the Oseltamivir-resistant H1N1 strain of IAV, respectively.

Influenza A virus-IN-4 (compound 23b), a derivative of Oseltamivir, is a highly effective neuraminidase inhibitor. It exerts potent inhibitory effects on influenza viruses [1].

Human ACE2 receptor-derived 23-amino acid peptide. Binds receptor binding domain (RBD) of insect-derived SARS-CoV-2 spike protein (KD = 1.3 μM for N-terminal biotinylated, insect-derived spike protein RBD; see Zhang et al preprint publication). Please note - unpublished, in-house data suggests approximately 75-fold lower affinity for insect-derived SARS-CoV-2 RBD than reported by Zhang et al.